JP Morgan Chase’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,542,476
| Closed | -$31.1M | – | 7225 |
|
|
2021
Q3 | $31.1M | Buy |
1,542,476
+110,950
| +8% | +$3.06M | ﹤0.01% | 1455 |
|
|
2021
Q2 | $53.4M | Buy |
1,431,526
+397,902
| +38% | +$12.2M | 0.01% | 1194 |
|
|
2021
Q1 | $26.4M | Buy |
1,033,624
+234,315
| +29% | +$5.98M | ﹤0.01% | 1525 |
|
|
2020
Q4 | $17.6M | Buy |
799,309
+206,171
| +35% | +$4.54M | ﹤0.01% | 1720 |
|
|
2020
Q3 | $10.9M | Buy |
593,138
+81,449
| +16% | +$1.69M | ﹤0.01% | 1973 |
|
|
2020
Q2 | $13M | Buy |
511,689
+54,583
| +12% | +$1.18M | ﹤0.01% | 1701 |
|
|
2020
Q1 | $8.4M | Sell |
457,106
-107,805
| -19% | -$2.1M | ﹤0.01% | 1876 |
|
|
2019
Q4 | $12.4M | Buy |
564,911
+97,622
| +21% | +$1.96M | ﹤0.01% | 1943 |
|
|
2019
Q3 | $6.71M | Sell |
467,289
-10,035
| -2% | -$143K | ﹤0.01% | 2447 |
|
|
2019
Q2 | $7.52M | Buy |
477,324
+31,602
| +7% | +$430K | ﹤0.01% | 2323 |
|
|
2019
Q1 | $6.53M | Buy |
445,722
+431,984
| +3,144% | +$4.96M | ﹤0.01% | 2376 |
|
|
2018
Q4 | $147K | Sell |
13,738
-45,280
| -77% | -$596K | ﹤0.01% | 4701 |
|
|
2018
Q3 | $900K | Buy |
59,018
+7,238
| +14% | +$105K | ﹤0.01% | 3987 |
|
|
2018
Q2 | $634K | Sell |
51,780
-69,168
| -57% | -$869K | ﹤0.01% | 4068 |
|
|
2018
Q1 | $1.16M | Buy |
120,948
+85,525
| +241% | +$922K | ﹤0.01% | 3590 |
|
|
2017
Q4 | $320K | Buy |
35,423
+33,823
| +2,114% | +$249K | ﹤0.01% | 4262 |
|
|
2017
Q3 | $8K | Sell |
1,600
-1,770
| -53% | -$6.44K | ﹤0.01% | 4755 |
|
|
2017
Q2 | $11K | Buy |
3,370
+1,270
| +60% | +$4.01K | ﹤0.01% | 4650 |
|
|
2017
Q1 | $7K | Buy |
+2,100
| New | +$5.91K | ﹤0.01% | 4868 |
|
|
2016
Q4 | – | Sell |
-13,278
| Closed | -$78K | – | 5204 |
|
|
2016
Q3 | $78K | Sell |
13,278
-6,864
| -34% | -$24.1K | ﹤0.01% | 3924 |
|
|
2016
Q2 | $60K | Sell |
20,142
-104,558
| -84% | -$429K | ﹤0.01% | 4005 |
|
|
2016
Q1 | $669K | Sell |
124,700
-2,925
| -2% | -$18.5K | ﹤0.01% | 3235 |
|
|
2015
Q4 | $1.51M | Sell |
127,625
-10,850
| -8% | -$124K | ﹤0.01% | 2909 |
|
|
2015
Q3 | $1.14M | Sell |
138,475
-17,175
| -11% | -$198K | ﹤0.01% | 3042 |
|
|
2015
Q2 | $2.17M | Sell |
155,650
-59,625
| -28% | -$1.09M | ﹤0.01% | 2868 |
|
|
2015
Q1 | $5.17M | Sell |
215,275
-88,350
| -29% | -$1.99M | ﹤0.01% | 2325 |
|
|
2014
Q4 | $5M | Sell |
303,625
-47,325
| -13% | -$546K | ﹤0.01% | 2413 |
|
|
2014
Q3 | $4.47M | Sell |
350,950
-4,625
| -1% | -$69.7K | ﹤0.01% | 2439 |
|
|
2014
Q2 | $8.03M | Buy |
355,575
+92,450
| +35% | +$1.68M | ﹤0.01% | 1853 |
|
|
2014
Q1 | $7.43M | Buy |
+263,125
| New | +$9.78M | ﹤0.01% | 1877 |
|
Other funds holding DRNA
JP Morgan Chase's DRNA Position: Q4 2021 in Review
JP Morgan Chase sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,542,476 shares — an estimated $31.1M sold.
JP Morgan Chase first reported a position in DRNA in Q1 2014 and held it in 30 quarters. The position peaked at $53.4M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- JP Morgan Chase reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- JP Morgan Chase sold 1,542,476 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $31.1M.
- JP Morgan Chase first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 30 quarters.
- JP Morgan Chase's Dicerna Pharmaceuticals, Inc. position peaked at $53.4M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.